Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology,

Slides:



Advertisements
Similar presentations
Update on Ovarian Cancer
Advertisements

Advances and Emerging Therapy for Lung Cancer
AGO-Austria Phase-III Studie: HECTOR
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.
O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.
Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Mar 5th, 2007 Hua-His Wu, MD OB/GYN, VGH- TPE. H.H. Wu, MD Mar 5th, 2007 Epithelial ovarian cancer  Standard therapy A maximum cytoreductive surgery.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer Ignace Vergote, MD PhD University Hospitals Leuven, Belgium IGCS Santa.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
Ovarian Cancer Dr Helen Mackay.
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer 부산백병원 산부인과 R2 서영진.
Nab-paclitaxel Development in Gynecologic Malignancies Robert Coleman, MD, FACOG, FACS Director of Clinical Research Department of Gynecologic Oncology.
Cancer Center Stanford University Gynecologic Cancer Treatment ASCO 2006 Update: Gynecologic Cancers Amreen Husain, M.D. Assistant Professor Division of.
Are there benefits from chemotherapy to early endometrial cancer
Primary Debulking for Bulky Advanced Stage Ovarian Cancer Ginger J. Gardner, MD Director, Survivorship Program Gynecology Service, Department of Surgery.
Investigating the Role of Anti- Angiogenic Agents in Ovarian Cancer Carol Aghajanian, M.D. Chief, Gynecologic Medical Oncology Memorial Sloan-Kettering.
Be it resolved that… IP therapy should be the standard of care for women with optimally debulked Stage III ovarian cancer Not so fast… Michael A Bookman.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Gynecologic Malignancies Dr. David Edelmann Sharett Institute of Oncology Hadassah Medical Organization.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Proc ASCO 25: Abstract 5002 GOG0182-ICON5: Phase III Randomized Trial of Paclitaxel and Carboplatin vs Combinations with Gemcitabine, PEG-Lipososomal Doxorubicin,
Clique para editar o título mestre. Incorporation of bevacizumab in first-line treatment of advanced ovarian cancer: results and indications Ursula Matulonis,
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
Introduction Ignace Vergote, MD Department of Obstetrics and Gynaecology Gynaecologic Oncology Catholic University of Leuven Leuven, Belgium.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
Phase III Trial of Induction Gemcitabine (G) or Paclitaxel (T) Plus Carboplatin (C) Followed by Elective T Consolidation in Ovarian Cancer (OC), Stages.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Personalized therapy in ovarian cancer Dragos Median “Filantropia” Clinical Hospital, Bucharest.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Ovarian cancer update Kentucky cancer Registry 9/8/2016
Management of metastatic and recurrent head and neck cancer
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Adjuvant Radiation is Required for Gastric Cancer
Nab-paclitaxel in Ovarian Cancer
IMagyn050 YO39523/GOG-3015/ENGOT-ov39 Recruitment Update
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma
Presentation transcript:

Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics

Development of Intraperitoneal Chemotherapy 1950’s:First use of intraperitoneal chemotherapy for malignant ascites1950’s:First use of intraperitoneal chemotherapy for malignant ascites 1968: Long-term peritoneal access device1968: Long-term peritoneal access device 1978: Demonstration of slow peritoneal clearance of some drugs1978: Demonstration of slow peritoneal clearance of some drugs 1984: Feasibility of intermittent large volume intraperitoneal therapy1984: Feasibility of intermittent large volume intraperitoneal therapy 1996: First report of a survival benefit for IP vs. IV chemotherapy in advanced ovarian cancer1996: First report of a survival benefit for IP vs. IV chemotherapy in advanced ovarian cancer

Peritoneal: Plasma Ratio DrugPeak AUC Cisplatin Carboplatin Melphalan Adriamycin FU MTX Paclitaxel ---1,000

Intraperitoneal Therapy: Ovarian Cancer Rationale:Rationale: –Major route of spread within the peritoneal cavity –Ability to reduce tumor volume with debulking –Residual peritoneal tumor exposed to increased concentration of drug for prolonged period of time Limitations:Limitations: –Poor tumor penetration of bulk disease –Less exposure of extra-peritoneal disease to drug Complications:Complications: –Obstruction to flow or inadequate distribution –Infection: peritonitis, abdominal wall or catheter –Intestinal perforation

GOG #104 SWOG #8501 Ovarian cancer Stage III Stratify: < 0.5 cm > cm RANDOMIZE Cisplatin 100 mg/m 2 IV Cyclophosphamide 600 mg/m 2 IV q 21 days x 6 Cisplatin 100 mg/m 2 IP Cyclophosphamide 600 mg/m 2 IV q 21 days x 6 Second look Laparotomy

GOG #104 GOG #104 Alberts et.al. NEJM Dec 1996 Cyclophosphamide and Cisplatin INTRAPERITONEAL INTRAPERITONEALCyclophosphamide and Cisplatin INTRAVENOUS INTRAVENOUS Path CR 47%36% Survival 49 mo 41 mo p=.02

Consensus: GOG 104 The benefits of IP chemotherapy seen in GOG 104 are not greater than the benefits of the new agent, paclitaxel

GOG #114 Ovarian cancer Stage III < 1.0 cm RANDOMIZE Cisplatin 75 mg/m 2 IV Paclitaxel 135 mg/m 2 IV q 21 days x 6 Carboplatin AUC=9 x 2 IV then Cisplatin 100 mg/m 2 IP Paclitaxel 135 mg/m 2 IV q 21 days x 6 Second look Laparotomy Cisplatin 75 mg/m 2 IV Cyclophosphamide 750mg/m 2 IV q 21 days x 6

GOG #114 Ovarian cancer Stage III < 1.0 cm RANDOMIZE Cisplatin 75 mg/m 2 IV Paclitaxel 135 mg/m 2 IV q 21 days x 6 Carboplatin AUC=9 x 2 IV then Cisplatin 100 mg/m 2 IP Paclitaxel 135 mg/m 2 IV q 21 days x 6 Second look Laparotomy Cisplatin 75 mg/m 2 IV Cyclophosphamide 750mg/m 2 IV q 21 days x 6 X

GOG #114 GOG #114 Markman et.el. JCO Feb 2001 IV Carbo IV Taxol IP Cisplatin IV Taxol IV Cisplatin PFS 27.6 mos 22.5 mos P=.01 Overall Survival 63.2 mos 52.5 mos P=.05

Consensus: GOG 114 The benefits of IP in GOG 114 are likely explained by the use of eight cycles of chemotherapy, not the use if IP administration (see GOG 182)

GOG #172 Armstrong et.al. Abs #803, ASCO 2002 Ovarian cancer Optimal (<1cm) Stage III Stratify: Gross residual Planned 2 nd look RANDOMIZE BRCA Analysis DNA Banking Paclitaxel 135 mg/m 2 /24h Cisplatin 75 mg/m 2 q 21 days x 6 Paclitaxel 135 mg/m 2 /24h Cisplatin 100 mg/m 2 IP D2 Paclitaxel 60 mg/m 2 IP D8 q 21 days x 6 Second look Laparotomy (if chosen)

Treatment Regimens Every 21 days x 6 Regimen 1 Intravenous Regimen 2 Intraperitoneal D1: IV Paclitaxel (135mg/m 2 /24h) D2: IV Cisplatin (75mg/m 2 ) D1: IV Paclitaxel (135mg/m 2 /24h) D2: IP Cisplatin (100mg/m 2 ) D8: IP Paclitaxel (60mg/m 2 ) D1 IV D2 IV D1 IV D2 IP D8 IP

GOG #172: Non-hematologic toxicities Armstrong et.al. Abs #803, ASCO 2002 IVIP GI G3/424%46% Renal G3/41%6% Fatigue G3/45%17% Pain G3/41%11% Metabolic G3/47%24% Neuro G3/49%19%

GOG #172: Hematologic Toxicities GOG #172: Hematologic Toxicities Armstrong et.al. Abs #803, ASCO 2002 IVIP Leukopenia G414%31% Infection G3/45%16% Plts G3/44%12 %

Courses of Protocol Therapy by Regimen # courses Treatment Assignment IntravenousIntraperitoneal Assigned Treatment (AT) AT or Carboplatin* Assigned Treatment (AT) AT or Crossover to IV cisplatin AT or Crossover to IV cisplatin or carboplatin* 02 (1%) 0 (0%)16 (8%)5 (2%) 4 (2%) 18 (4%) 7 (3%)38 (19%)21 (10%) 10 (5%) 29 (4%) 4 (2%)30 (15%)20 (10%) 6 (3%) 311 (5%) 6 (3%)14 (7%)9 (4%) 4 (2%) 42 (1%) 0 (0%)10 (5%)5 (2%) 4 (2%) 5 11 (5%)12 (6%) 7 (3%) 6174 (83%)189 (90%)86 (42%)133 (65%)170 (83%) * Carboplatin substituted for cisplatin

Second Look Finding IVIP Negative 2 nd look 35 (41%) 46 (57%) Positive 2 nd look 37 (44%) 23 (28%) 2 nd look contraindicated 13 (15%) 12 (15%) Total 85 (100%) 81 (100%) GOG #172: Second Look Results

GOG #172: Survival Regimen 1 Intravenous Regimen 2 Intraperitoneal Progression-free18.3 mos23.8 mos Overall Survival49.5 mos66.9 mos

Relative Risk: IP vs. IV Therapy, GOG #172 Relative Risk95% CIp-value PFS OS

Figure 1

Figure 2

Modulating Toxicity of IP Therapy New approaches to improve toxicity profileNew approaches to improve toxicity profile –Type of catheter used –Timing of catheter placement –Timing of chemotherapy relative to surgeryrelative to surgery relative to catheter placementrelative to catheter placement –Agents used Successful use of IP therapy requires:Successful use of IP therapy requires: –Training –Skill –Experience –Dedication

Consensus: 2005 The toxicities, inconvenience and cost of IP therapy are justified by the improved survival seen with this treatmentThe toxicities, inconvenience and cost of IP therapy are justified by the improved survival seen with this treatment New, targeted therapies are likely to be more effective in patients who have an excellent response to chemotherapyNew, targeted therapies are likely to be more effective in patients who have an excellent response to chemotherapy While we work to improve the tolerability and toxicities of IP therapy, it remains the most effective means of treating ovarian cancer todayWhile we work to improve the tolerability and toxicities of IP therapy, it remains the most effective means of treating ovarian cancer today